Telimaa 1987.

Methods	Location: University of Oulu, Finland No. of centres: 1 Recruitment period: not stated
Participants	Inclusion criteria: advanced endometriosis Exclusion criteria: NS No. randomised: 60 No. analysed: 51 (pain), 59 (pregnancy)
Interventions	Post‐surgical medical therapy Gr A (n = 20): danazol oral 600 mg daily x 180 days Gr B (n = 20): MPA 100 mg daily x 180 days Gr C (n=20): placebo
Outcomes	Pain scores AFS scores Pregnancy rates Patient satisfaction Adverse drug reactions: weight gain, breakthrough bleeding, acne
Notes	Power calculation: NS Funding: Research and Science Foundation Farmos Ltd, Turku; Cultural Foundation of Keski‐Pohjanmaa, Finland; Farmos Group, Turku, Finland supplied drugs
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomized" no information on method of sequence generation
Allocation concealment (selection bias)	Unclear risk	not mentioned
Blinding (performance bias and detection bias) All outcomes	Low risk	double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Numbers and reasons for post randomisation exclusions similar in each group. 3,2,3 excluded in groups A,B & C due to pregnancy. 1 adverse event in placebo group
Selective reporting (reporting bias)	Low risk	important outcomes of pregnancy recurrence and pain reported
Other bias	Low risk	groups appear comparable at baseline and authors state that" no other medication was used during the trial"